Literature DB >> 8257144

Pharmacokinetics and serum bactericidal titers of ciprofloxacin and ofloxacin following multiple oral doses in healthy volunteers.

D Israel1, J G Gillum, M Turik, K Harvey, J Ford, H Dalton, M Towle, R Echols, A H Heller, R Polk.   

Abstract

Fourteen adult males participated in a randomized three-way crossover study to compare the pharmacokinetics and serum bactericidal titers (SBTs) of 500 mg of ciprofloxacin (regimen A), 750 mg of ciprofloxacin (regimen B), and 400 mg of ofloxacin (regimen C) administered every 12 h for seven doses. Mean steady-state peak concentrations in serum for regimens A, B, and C were 3.0, 4.4, and 6.5 micrograms/ml, respectively (P < 0.01, all comparisons) and mean half-lives were 4.5, 4.3, and 6.5 h, respectively (P < 0.05, C versus A and B). Mean steady-state areas under the concentration-time curve were 14.1, 21.1, and 48.1 micrograms/h/ml for regimens A, B, and C, respectively (P < 0.05, all comparisons). SBTs were determined at different times postdose for three isolates each of Streptococcus pneumoniae, Staphylococcus aureus, Escherichia coli, Enterobacter cloacae, and Pseudomonas aeruginosa. Mean steady-state peak SBTs for regimens A, B, and C, respectively, were as follows: S. pneumoniae, < 1:2, 1:8, 1:8, S. aureus, 1:16, 1:16, 1:16; E. coli, 1: > or = 128, 1: > or = 128, 1:64; E. cloacae, 1: > or = 128, 1: > or = 128, 1:64; P. aeruginosa, 1:8, 1:8, 1:2. These differences in SBTs within each genus were statistically significant. The majority of predicted SBTs were within one dilution of measured SBTs. Areas under the serum bactericidal time curves for E. coli, E. cloacae, and P. aeruginosa were significantly higher for ciprofloxacin; areas under the serum bactericidal time curves for S. pneumoniae and S. aureus were significantly greater for ofloxacin. Ofloxacin achieved higher concentrations in serum than ciprofloxacin, but differences in in vitro activity were a more important determinant of SBTs.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8257144      PMCID: PMC192249          DOI: 10.1128/AAC.37.10.2193

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  Mathematical examination of dual individualization principles (I): Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin.

Authors:  J J Schentag; D E Nix; M H Adelman
Journal:  DICP       Date:  1991-10

2.  Correlation of predicted serum bactericidal activities and values measured in volunteers.

Authors:  G Drusano; H Standiford; P Ryan; W McNamee; B Tatem; S Schimpff
Journal:  Eur J Clin Microbiol       Date:  1986-02       Impact factor: 3.267

3.  Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule.

Authors:  R Wise; D Griggs; J M Andrews
Journal:  Rev Infect Dis       Date:  1988 Jan-Feb

4.  Antibacterial activity of the metabolites of ciprofloxacin and its significance in the bioassay.

Authors:  H J Zeiler; U Petersen; W Gau; H J Ploschke
Journal:  Arzneimittelforschung       Date:  1987-02

5.  Analysis of a new method for assessing activity of combinations of antimicrobials: area under the bactericidal activity curve.

Authors:  S L Barriere; E Ely; J E Kapusnik; J G Gambertoglio
Journal:  J Antimicrob Chemother       Date:  1985-07       Impact factor: 5.790

6.  Serum bactericidal activity of ciprofloxacin and ofloxacin in volunteers.

Authors:  K Machka; D Milatovic
Journal:  Eur J Clin Microbiol       Date:  1987-02       Impact factor: 3.267

7.  Bactericidal activity of ciprofloxacin compared with that of cefotaxime in normal volunteers.

Authors:  H C Standiford; G L Drusano; A Forrest; B Tatem; K Plaisance
Journal:  Antimicrob Agents Chemother       Date:  1987-08       Impact factor: 5.191

8.  Bactericidal activity of ciprofloxacin in serum and urine against Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, Staphylococcus aureus and Streptococcus faecalis.

Authors:  H Lagast; M Husson; J Klastersky
Journal:  J Antimicrob Chemother       Date:  1985-09       Impact factor: 5.790

9.  Correlation of serum bactericidal activity with antimicrobial agent level and minimal bactericidal concentration.

Authors:  C W Stratton; M P Weinstein; L B Reller
Journal:  J Infect Dis       Date:  1982-02       Impact factor: 5.226

10.  Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients.

Authors:  A Forrest; D E Nix; C H Ballow; T F Goss; M C Birmingham; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

View more
  17 in total

1.  Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model.

Authors:  P D Lister; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Cellular accumulation and activity of quinolones in ciprofloxacin-resistant J774 macrophages.

Authors:  Jean-Michel Michot; Marie F Heremans; Nancy E Caceres; Marie-Paule Mingeot-Leclercq; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

3.  Ex vivo antibacterial properties of rufloxacin compared with those of norfloxacin in a study with healthy volunteers.

Authors:  L Aguilar; I P Balcabao; P Salvá; M Martín; J Costa; J Prieto; R Dal-ré
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

4.  Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis.

Authors:  Y Dong; X Zhao; B N Kreiswirth; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

Review 5.  Management of polyomavirus-associated nephropathy in renal transplant recipients.

Authors:  Dirk R J Kuypers
Journal:  Nat Rev Nephrol       Date:  2012-04-17       Impact factor: 28.314

6.  Comparative serum bactericidal activities of three doses of ciprofloxacin administered intravenously.

Authors:  M Dan; F Poch; C Quassem; R Kitzes
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

Review 7.  Ofloxacin. A reappraisal of its use in the management of genitourinary tract infections.

Authors:  S V Onrust; H M Lamb; J A Balfour
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

8.  Single-dose rufloxacin versus 3-day norfloxacin treatment of uncomplicated cystitis: clinical evaluation and pharmacodynamic considerations.

Authors:  G Del Río; F Dalet; L Aguilar; J Caffaratti; R Dal-Ré
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

9.  Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages.

Authors:  Maritza Barcia-Macay; Cristina Seral; Marie-Paule Mingeot-Leclercq; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

10.  In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis.

Authors:  B JI; N Lounis; C Truffot-Pernot; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.